ACADIA Pharmaceuticals Inc. (ACAD)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

ACADIA Pharmaceuticals Inc. (ACAD) is down 21.8% since the beginning of the year. At $21 per share, ACAD is trading 26.3% below its 52-week high of $28. Investors who bought $1,000 worth of ACAD shares 5 years ago would now be looking at an investment worth $896.

ACADIA Pharmaceuticals Inc. (ACAD) has returned -21.79% so far this year and -2.68% over the past 12 months. Over the last ten years, ACAD has returned -5.32% per year, falling short of the S&P 500 Index benchmark, which averaged 13.75% annually.

Based on dividend-adjusted daily data since May 27, 2004, ACAD's average daily return is +0.15%, while the average monthly return is +2.72%. At this rate, an investment would double in approximately 2.2 years.

Historically, 51% of months were positive and 49% were negative. The best month was Nov 2012 with a return of +121.3%, while the worst month was Sep 2009 at -70.7%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 7 months.

On a daily basis, ACAD closed higher 48% of trading days. The best single day was Nov 27, 2012 with a return of +136.1%, while the worst single day was Sep 1, 2009 at -65.8%.

ACADIA Pharmaceuticals Inc. has an annualized alpha of 24.79%, beta of 1.46, and R2 of 0.10 versus S&P 500 Index. Calculated based on daily prices since May 28, 2004.

• This stock captured 192.06% of S&P 500 Index gains and 177.23% of its losses - amplifying both gains and losses, but participating more in upside than downside.
• R2 of 0.10 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ACAD ranks 35 for risk / return — below 35% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The table below present risk-adjusted performance metrics for ACADIA Pharmaceuticals Inc. (ACAD) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the ACADIA Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the ACADIA Pharmaceuticals Inc. was 96.29%, occurring on Nov 12, 2010. Recovery took 645 trading sessions.

The current ACADIA Pharmaceuticals Inc. drawdown is 63.35%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of ACADIA Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how ACADIA Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.